Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer

Ming Ming Bi*, Bin Shang*, Zhou Wang & Gang Chen

Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

Keywords
CXCR4; lymph node metastasis; non-small cell lung cancer; VEGF-C.

Correspondence
Gang Chen, Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, Shandong 250021, China.
Tel: +86 156 2186 3187
Email: chengang0501@yeah.net

*Ming Ming Bi and Bin Shang contributed equally to this study.

Abstract
Background: This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC).

Methods: Tumor specimens, lymph nodes, and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcription-PCR and immunohistochemistry assays were conducted to evaluate messenger RNA (mRNA) and protein expression of CXCR4 and VEGF-C. Logistic regression analysis was performed to determine the independent risk factors for lymph node metastasis in NSCLC.

Results: CXCR4 and VEGF-C mRNA expression were observed in 78 (70.9%) and 64 (58.2%) lung cancer tissues, while CXCR4 and VEGF-C protein expression were observed in 76 (69.9%) and 58 (52.7%) lung cancer tissues, respectively. The expression rates of CXCR4 and VEGF-C mRNA in metastatic lymph nodes were 84.8% and 66.7%, which were higher than that in non-metastatic lymph nodes (27.3% and 18.2%), respectively. Logistic regression analysis revealed that positive expressions of CXCR4 and VEGF-C mRNA were independent risk factors for lymph node metastasis in NSCLC. Furthermore, combined expression of CXCR4 and VEGF-C showed a much higher odds ratio than CXCR4 or VEGF-C expression alone.

Conclusions: CXCR4 and VEGF-C were highly expressed in lung cancer tissues and metastatic lymph nodes. CXCR4 and VEGF-C expression levels were significantly correlated with lymph node metastasis in NSCLC. CXCR4 and VEGF-C might synergically promote lymphatic metastasis in lung cancer and might be a clinical predictor of lymph node metastasis in NSCLC patients.

Introduction
Primary lung cancer is the leading cause of cancer-related death. Although recent advances have been made in therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, the prognosis of lung cancer remains unsatisfactory.1–3 High incidence of lymphatic metastasis is a chief cause of morbidity and mortality in lung cancer patients, and is closely related to poor prognosis.4 To improve prognosis, it is essential to clarify the biological characteristics of lymph node metastasis in lung cancer. However, the mechanisms underlying the lymphatic spread of tumor cells in lung cancer are still not fully understood.

Previous studies have indicated that lymph node metastasis in lung cancer is positively correlated with tumor chemotactic migration and lymphangiogenesis.5 Recent research has revealed that high expression levels of chemokines are related to poor prognosis and chemotherapy tolerance in cancer patients.6 CXCR4 is a chemokine receptor that plays a critical role in the process of lymphocyte homing to lymphatic vessels and secondary lymphoid organs, including the lymph nodes. It has also been reported that CXCR4 is implicated in the chemotactic migration of cancer cells.7 VEGF-C is another factor strongly correlated to lymphatic metastasis. VEGF-C binds to VEGFR-3, which could induce lymphangiogenesis, and mediate tumor cell dissemination and the formation of lymph node metastasis.8–10
However, studies of the predictive value of CXCR4 in lymph node metastasis of cancer have lead to highly controversial conclusions. It has been reported that CXCR4 protein expression cannot be considered a predictive indicator of lymph node metastasis.11 Few reports have focused on the relationship between VEGF-C expression and lymph node metastasis in lung cancer. Thus, to clarify the correlation between CXCR4 and VEGF-C expression and lymph node metastasis in lung cancer, CXCR4 and VEGF-C expression was evaluated by PCR and immunohistochemistry in non-small cell lung cancer (NSCLC) patients with and without lymph node metastases.

**Methods**

**Patients**

One hundred and ten patients with primary NSCLC who underwent complete lobectomy without any preoperative therapy at the Department of Thoracic Surgery of the Provincial Hospital Affiliated to Shandong University from March 2013 to January 2014 were included in this study. Histological cell typing was conducted according to World Health Organization (WHO) classifications and systematic lymph node dissection was performed according to American Thoracic Society lymph node mapping. Pathologic stage was classified based on the 2009 International Union Against Cancer tumor node metastasis (TNM) classification. Written informed consent was obtained from each patient. The ethical committee of the Provincial Hospital Affiliated to Shandong University approved the study protocol (Ethical Review of Medical Research on Human Beings No. 2015–032).

During surgery, tumor specimens, lymph nodes, and normal lung tissues were obtained and quickly frozen in liquid nitrogen for RNA extraction, or immediately fixed in 10% neutral-buffered formalin for routine pathologic examination. In total, 514 lymph nodes were obtained, among which 157 positive nodes with malignant neoplasms and 90 negative nodes without malignant neoplasms were selected. We also randomly selected 63 normal lung tissues (at a distance of 5 cm from the tumor and confirmed by pathology as normal lung tissues) as the control.

**Real-time fluorescence quantitative PCR**

Messenger RNA (mRNA) expression of CXCR4 and VEGF-C was analyzed by real-time fluorescence quantitative reverse transcription-PCR (qRT-PCR). Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) and reverse transcribed to cDNA according to the manufacturer’s instructions (Takara, Otsu, Japan). SYBR-Green was used to detect the qRT-PCR products in a LightCycler 480 Real-Time PCR system (Roche Diagnostics, Indianapolis, IN, USA). The primer sequences of CXCR4 and VEGF-C were as follows: CXCR4: forward primer: 5'-GGCCAAGTTCTTGTTGTGTAG-3', reverse primer: 5'-ACGTTCCACGGGAATGGAG-3'; VEGF-C: forward primer: 5'-AGCAGGAGCTACCTCAGAAAGAC-3', reverse primer: 5'-TTTAGACATGCATCGCGAGGAA-3'.

The β-actin gene was amplified as an internal normalization to calculate the relative mRNA expression.

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded specimens of lung cancer tissue and lymph nodes were collected. Sections were cut and mounted on poly-L-lysine-coated glass slides. Immunohistochemical staining was performed using the streptavidin peroxidase method. The primary antibodies used in this study were mouse anti-human CXCR4 and VEGF-C monoclonal antibodies with a dilution of 1:200 (ThermoFisher Scientific, Fremont, CA, USA). Negative controls were set by replacing the primary antibody with phosphate buffered saline. Three independent pathologists blinded to the clinical data evaluated all sections. In cases of a discrepancy, the pathologists reached agreement by reanalysis and discussion. The immunostaining results were analyzed using a semi-quantitative scoring system based on the combined evaluation of intensity and proportion of the positively-stained cells. Staining intensity was divided into four grades: 0 = no reactivity, 1 = low, 2 = moderate, and 3 = strong. The proportion of stained tumor cells was also divided into four grades: 0 = 0–5%, 1 = 5–10%, 2 = 11–50% and 3 ≥ 50%. CXCR4 or VEGF-C staining was considered positive when the total score reached 4–9.

**Statistical analysis**

All data were collected and analyzed using SPSS version 19.0 (IBM Corp., Armonk, NY, USA). Chi-square or Fisher’s exact tests were used to evaluate the differences in CXCR4 and VEGF-C expression between the groups. Logistic regression analysis was performed to determine the relevant risk factors for lymph node metastasis in lung cancer. Differences with P values < 0.05 were considered statistically significant.

**Results**

**Clinical characteristics of the patients**

In total, 110 patients with primary NSCLC who underwent complete resection were included in this study. The study population included 78 men and 32 women with an average age of 57 years (range 34–74). Forty-three cases were classified as squamous cell carcinomas, 61 as adenocarcinomas,
five as adenosquamous carcinomas, and one case was classified as large cell carcinoma. There were 66 patients with N1 stage and 44 with N0 stage. The clinicopathological features of the NSCLC patients are summarized in Tables 1 and 2.

**CXCR4 expression and its correlation with clinicopathological factors in non-small cell lung cancer (NSCLC)**

Messenger RNA expression levels of CXCR4 were detected in lung tumor tissues, lymph nodes, and normal lung tissues. The results are shown in Table 1 and Figure 1. CXCR4 mRNA was highly expressed in 78 lung tumor tissues (70.9%) among the 110 cases. CXCR4 mRNA was detected in 58 (87.9%) out of 66 lung cancer patients with stage N1–2, and 20 (45.5%) out of 44 cases of primary tumors in lung cancer patients with stage N0.

Immunohistochemical staining revealed CXCR4 protein expression in the cytoplasm of lung cancer cells (Table 2 and Fig 2). No positive staining was observed in the adjacent normal lung tissues. In 110 cases of primary tumors, CXCR4 protein expression was detected in 76 cases (69.1%). CXCR4 protein was detected in 56 (84.8%) out of 66 lung cancer patients with stage N1–2, and 20 (45.5%) out of 44 cases of primary tumors in lung cancer patients with stage N0.

There was no significant correlation in CXCR4 mRNA or protein expression in lung cancer tissues to patients’ clinical characteristics, such as age, gender, histology, and differentiation (P > 0.05).

**VEGF-C expression and its correlation with clinicopathological factors in NSCLC**

Messenger RNA expression levels of VEGF-C were detected in lung tumor tissues, lymph nodes, and normal lung tissues (Fig 1). VEGF-C mRNA was highly expressed in 64 lung tumor tissues (58.2%) among the 110 cases. VEGF-C mRNA was detected in 46 (69.7%) out of 66 lung cancer patients with stage N1–2, and 18 (40.9%) out of 44 lung cancer patients with stage N0. VEGF-C mRNA expression in lung cancer tissues was significantly correlated with histology, stage, tumor size, and lymph node metastasis (P < 0.05).

### Table 1 mRNA expression detected by qRT-PCR

| Feature          | CXCR4 (+) | CXCR4 (-) | VEGF-C (+) | VEGF-C (-) | P     |
|------------------|-----------|-----------|------------|------------|-------|
| Gender           |           |           |            |            |       |
| Male             | 54        | 24        | 65         | 32         | 0.65  |
| Female           | 24        | 8         | —          | 22         | 0.20  |
| Age              |           |           |            |            |       |
| ≤ 60             | 50        | 16        | 24         | 42         | 0.17  |
| > 60             | 28        | 16        | —          | 22         |       |
| Histology        |           |           |            |            |       |
| Squamous cancer  | 35        | 8         | 31         | 12         | 0.04  |
| Adenocarcinoma   | 39        | 22        | —          | 31         |       |
| Others           | 4         | 2         | —          | 2          |       |
| Differentiation  |           |           |            |            |       |
| High and middle  | 60        | 28        | 50         | 38         | 0.63  |
| Low              | 18        | 4         | —          | 14         |       |
| TNM              |           |           |            |            |       |
| I-II             | 32        | 28        | —          | 24         |       |
| III-IV           | 46        | 4         | —          | 40         |       |
| T                |           |           |            |            |       |
| T1–2             | 42        | 26        | 32         | 36         |       |
| T3–4             | 36        | 6         | —          | 32         |       |
| N                |           |           |            |            |       |
| N0               | 20        | 24        | 18         | 26         |       |
| N1–2             | 58        | 8         | 46         | 20         |       |
| CXCR4            | (+)       | —         | —          | 46         | 0.83  |
|                  | (-)       | —         | —          | 18         |       |
| Total            | 78        | 32        | 64         | 46         |       |

* Squamous/adenocarcinoma. ** Fisher’s exact test. Bold text indicates that P < 0.05 was statistically significant. mRNA, messenger RNA; qRT, quantitative reverse transcription; TNM, tumor node metastasis.

### Table 2 CXCR4 and VEGF-C expression in lung cancer detected by immunohistochemistry

| Feature          | CXCR4 (+) | CXCR4 (-) | VEGF-C (+) | VEGF-C (-) | P     |
|------------------|-----------|-----------|------------|------------|-------|
| Gender           |           |           |            |            |       |
| Male             | 52        | 26        | 38         | 40         | 0.50  |
| Female           | 24        | 8         | —          | 20         |       |
| Age              |           |           |            |            |       |
| ≤ 60             | 50        | 16        | 40         | 26         | 0.05  |
| > 60             | 26        | 18        | —          | 18         |       |
| Histology        |           |           |            |            |       |
| Squamous CA      | 33        | 10        | 27         | 16         | 0.163 |
| Adenocarcinoma   | 39        | 22        | —          | 29         |       |
| Others           | 4         | 2         | —          | 1          |       |
| Differentiation  |           |           |            |            |       |
| High and middle  | 58        | 30        | 42         | 46         | 0.06  |
| Low              | 18        | 4         | —          | 16         |       |
| TNM              |           |           |            |            |       |
| I-II             | 30        | 30        | 22         | 38         |       |
| III-IV           | 46        | 4         | 36         | 14         |       |
| T                |           |           |            |            |       |
| T1–2             | 40        | 28        | 28         | 40         |       |
| T3–4             | 36        | 6         | 30         | 12         |       |
| N                |           |           |            |            |       |
| N0               | 20        | 24        | 14         | 30         |       |
| N1–2             | 56        | 10        | 44         | 22         |       |
| CXCR4            | (+)       | —         | —          | 23         | 0.02  |
|                  | (-)       | —         | —          | 6          |       |
| Total            | 76        | 34        | 58         | 52         |       |

* Squamous/adenocarcinoma. ** Fisher’s exact test. Bold text indicates that P < 0.05 was statistically significant. TNM, tumor node metastasis.
Immunohistochemical staining revealed VEGF-C protein expression. No positive staining was observed in the adjacent normal lung tissues. VEGF-C protein expression was detected in 58 (52.7%) out of 110 cases of primary tumors. VEGF-C protein was detected in 44 (66.7%) out of 66 lung cancer patients with stage N1–2, and in 14 (31.8%) out of 44 lung cancer patients with stage N0. VEGF-C protein expression in lung cancer tissues was significantly higher in patients with stage N1–2 compared to those with stage N0.

**Figure 1** Quantitative reverse transcription-PCR analysis to detect CXCR4 and VEGF-C expression in non-small cell lung cancer tissue. Relative messenger RNA (mRNA) levels of (a) CXCR4 and (b) VEGF-C.

**Figure 2** Immunohistochemistry assay of CXCR4 in non-small cell lung cancer tissue and metastatic lymph node tissue. CXCR4 expression in (a) squamous cell lung cancer 200x, (b) lung adenocarcinoma 200x, and (c) metastatic lymph nodes 200x. (d) Immunohistochemical scores of CXCR4 were calculated in lymph node metastasis (N1–2) and non-lymph node metastasis groups (N0).
correlated with stage, tumor size, and lymph node metastasis ($P < 0.05$) (Fig 3).

Moreover, both CXCR4 and VEGF-C mRNA were highly expressed in 48 cases (43.6%), while CXCR4 and VEGF-C protein expression was observed in 46 cases (41.8%). Interestingly, we determined that CXCR4 protein expression in lung cancer tissues was correlated with VEGF-C expression ($\chi^2 = 6.00; P = 0.022$).

**Logistic regression analysis**

Multivariate analysis was performed to evaluate CXCR4 and VEGF-C expression as risk factors of lymph node metastasis in lung cancer using the logistic regression model (Table 3). Positive expression of CXCR4 mRNA (odds ratio [OR] 9.771; $P = 0.000$) and VEGF-C mRNA (OR 5.190; $P = 0.002$) were independent risk factors for lymph node metastasis in lung cancer. No significant

**Table 3** Logistic multi-factor regression analysis for CXCR4 and VEGF-C expression

| Factor     | $P$  | OR    | 95% CI for OR |
|------------|------|-------|---------------|
| Gender     | 0.885| 1.094 | 0.322–3.718   |
| Age        | 0.921| 1.055 | 0.367–3.033   |
| Histology  | 0.196| 2.116 | 0.679–6.597   |
| Differentiation | 0.278 | 2.180 | 0.533–8.913   |
| T          | 0.251| 0.510 | 0.161–1.609   |
| CXCR4      | 0.000| 9.771 | 3.212–29.724  |
| VEGF-C     | 0.002| 5.190 | 1.811–14.873  |

Bold text indicates that $P < 0.05$ was statistically significant. CI, confidence interval; OR, odds ratio.
Cancer cells can be attracted and activate the chemokine system in a manner that benefits both local tumor growth and distant dissemination.21,22 Cancer cells can be attracted and activated by chemokines through chemokine receptors on their cell membranes.23 CXCR4 is widely expressed in more than 23 different types of malignant tumors including kidney, lung, brain, prostate, breast, pancreas, ovarian, and melanomas. CXCR4 could induce multiple oncogenic alterations and promote survival, proliferation, invasion, metastasis, and therapeutic resistance of tumor cells through integrating with its ligand, CXCL12.13,24 High levels of CXCR4 expression were found in breast cancer cells and is thought to indicate the metastatic destination of tumor cells.15 Recently, Bertolini et al. reported that compared to NSCLC cells with low levels of CXCR4 expression, NSCLC cells with high CXCR4 expression levels demonstrated a capacity for high self-renewal and chemotherapeutic resistance.25 It is well known that tumor cell migration and metastasis processes share many similarities with leukocyte trafficking, which is critically regulated by chemokines and their receptors.26 Therefore, chemokine-mediated mechanisms might also be involved in the process of lymph node metastasis of cancer cells, just as the regulation of chemokines in lymphocyte trafficking. However, the predicted effect of CXCR4 on lymph node metastasis in NSCLC patients has not yet been clarified in previous studies.

Our study demonstrated that CXCR4 was highly expressed in lung cancer tissues and positive metastatic lymph nodes. Using multivariate analysis, we demonstrated that CXCR4 was an independent risk factor for lymph node metastasis in NSCLC.

On the other hand, lymph node metastasis has been related to increased intratumor and/or peritumor lymphangiogenesis. VEGF-C is an important regulator of lymphangiogenesis and an important mediator of tumor metastasis toward sentinel lymph nodes.27 Most likely, lymphatic metastasis involves both invasion toward surrounding lymphatic vessels and either induction of new lymphatic sprouts into the tumor or expansion of peritumor lymphatic vessels.28,29 Issa et al. reported that VEGF-C could enhance tumor cell chemoinvasion toward lymphatics binding with autologous ligation of tumor VEGFR-3, which is expressed in low levels when tumor cells are cultured in a three-dimensional environment, leading to an increase in the proteolytic activity of the tumor cells and thereby enhancing their migration potential.29 Using qRT-PCR and immunohistochemistry assays, we confirmed that VEGF-C was also highly expressed in lung cancer tissues and metastatic lymph nodes, and VEGF-C was an independent risk factor for lymph node metastasis in NSCLC. The results suggested VEGF-C might be involved in the molecular signals for lymphangiogenesis in NSCLC. The specific molecular pathway signals for lymphangiogenesis in lung cancer should be pursued in future analyses of tumor lymphatic metastasis.

Interestingly, our study indicated that CXCR4 protein expression in lung cancer tissues was correlated with VEGF-C expression. We also determined that combined CXCR4 and VEGF-C expression showed a much higher OR value than CXCR4 or VEGF-C expression alone. Yasuoka et al.’s study showed similar results in that the combination of cytoplasmic CXCR4 and VEGF-C

### Table 4 Logistic multi-factor regression analysis for combined positive expression of CXCR4 and VEGF-C

| Factor       | P     | OR   | 95% CI for OR     |
|--------------|-------|------|-------------------|
| Gender       | 0.413 | 1.651| 0.497–5.482       |
| Age          | 0.955 | 1.031| 0.357–2.977       |
| Histology    | 0.641 | 1.311| 0.420–4.096       |
| Differentiation | 0.428 | 1.825| 0.413–8.068       |
| T            | 0.203 | 0.434| 0.120–1.569       |
| Both positive| **0.000** | 35.545 | 8.306–152.118     |

Bold text indicates that P < 0.05 was statistically significant. CI, confidence interval; OR, odds ratio.
expression was correlated with lymph node metastasis more strongly than cytoplasmic CXCR4 or VEGF-C expression alone.12 Earlier studies have shown that VEGF-C stimulation could induce CXCR4 upregulation in lymphangiogenic endothelial cells.13 Taken together, these results provide evidence that marked expression of CXCR4 and VEGF-C may play an important role in tumor growth, angiogenesis, and metastasis. We speculated that CXCR4 and VEGF-C expression could synergistically promote tumor cell invasion to the lymphatics, possibly because CXCL12 binding to CXCR4 activates PI3K. The activated PI3K then rapidly generates phosphatidylinositol (3,4,5)-trisphosphate and initiates AKT activation.15 Activated AKT stimulates NF-kB activation and eventually upregulates COX-2 expression.10 COX-2 is reportedly increased in NSCLC. CXCR4 and VEGF-C expression were significantly correlated with lymph node metastasis in NSCLC. CXCR4 and VEGF-C expression, particularly in combination, might promote lymphatic metastasis in lung cancer and may potentially be a clinical predictor of lymph node metastasis in NSCLC patients.

There are some limitations to this study. The patient sample was derived from one institution in the same area, which may limit the generalization of our results. The small sample size and the fact that this is a primary study are also limitations. Further research is needed to validate the clinical significance of CXCR4 and VEGF-C.

In summary, CXCR4 and VEGF-C were highly expressed in metastatic lymph nodes and cancer tissues in NSCLC. CXCR4 and VEGF-C expression were significantly correlated with lymph node metastasis in NSCLC. CXCR4 and VEGF-C expression, particularly in combination, might promote lymphatic metastasis in lung cancer and may potentially be a clinical predictor of lymph node metastasis in NSCLC patients.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (NO. 81302021).

Disclosure

No authors report any conflict of interest.

References

1. Ma Q, Li P, Xu M et al. Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance. J Exp Clin Cancer Res 2012; 31: 99.
2. Ye J, Ren Z, Gu Q, Wang L, Wang J. Ku80 is differentially expressed in human lung carcinomas and upregulated in response to irradiation in mice. DNA Cell Biol 2011; 30: 987–94.
3. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 2012; 13: 287–97.
4. Darling GE, Li F, Patsios D et al. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer. Eur J Cardiothorac Surg 2015; 48: 684–90.
5. Jacobson O, Weiss ID. CXCR4 chemokine receptor overview: Biology, pathology and applications in imaging and therapy. Theranostics 2013; 3: 1–2.
6. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–6.
7. Yasuoka H, Kodama R, Tsujimoto M et al. Neuregulin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer 2009; 9: 220.
8. Das S, Ladell DS, Podgrabinska S et al. Vascular endothelial growth factor-C induces lymphangiogenic carcinomatosis, an extremely aggressive form of lung metastases. Cancer Res 2010; 70: 1814–24.
9. Karpanen T, Egeblad M, Karkkainen MJ et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786–90.
10. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192–8.
11. Guo J, Lou W, Ji Y, Zhang S. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. Oncol Lett 2013; 5: 1572–8.
12. Yasuoka H, Tsujimoto M, Yoshidome K et al. Cytoplasmic CXCR4 expression in breast cancer: Induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer 2008; 8: 340.
13. Zhuo W, Jia L, Song N et al. The CXCL12-CXCR4 chemokine pathway: A novel axis regulates lymphangiogenesis. Clin Cancer Res 2012; 18: 5387–98.
14. Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 2013; 3: 26–33.
15. Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res 2014; 124: 31–82.
16. Vicenzi E, Liò P, Poli G. The puzzling role of CXCR4 in human immunodeficiency virus infection. Theranostics 2013; 3: 18–25.
17. Burns JM, Summers BC, Wang Y et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201–13.
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: Tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013; 31: 490–8.

Tumor budding correlates with the protumor immune microenvironment and is an independent prognostic factor for recurrence of stage I lung adenocarcinoma. Chest 2015; 148: 711–21.

Prognostic significance of preoperative neutrophil-lymphocyte ratios in patients with stage I non-small cell lung cancer after complete resection. Ann Surg Oncol 2015; 22 (Suppl. 3): S1324–31.

Control of chemokine-guided cell migration by ligand sequestration. Cell 2008; 132: 463–73.

Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS ONE 2011; 6: e20898.

CXCR4, VEGF-C promote NSCLC metastasis

M.M. Bi et al. Thoracic Cancer 8 (2017) 634–641 © 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd